CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
Exhibit 10.34
SETTLEMENT AGREEMENT
between
INCYTE GENOMICS INC.
and
AFFYMETRIX, INC.
SETTLEMENT AGREEMENT
This Settlement Agreement (this "Agreement") is effective this 21st day
of December, 2001 (the "Effective Date"), between Incyte Genomics, Inc., a
Delaware corporation ("Incyte") and Affymetrix, Inc., a Delaware corporation
("Affymetrix") (collectively, the "Parties").
W I T N E S S E T H:
WHEREAS, the Parties have been involved in various disputes, which have
led to the commencement of certain actions and proceedings, including, but not
limited to, Affymetrix, Inc. v. Synteni, Inc. and lncyte Pharmaceuticals, Inc.,
Case Nos. C 99-21164 JF and C 99-21165 JF (N.D. Cal.); Incyte Genomics, Inc. v.
Affymetrix, Inc., Xxxx Xx. X 00- 00000 XX (N.D. Cal.); and the Incyte Opposition
to European Patent No. EP 0619321 (collectively, the "Matters");
WHEREAS, in the Matters, Affymetrix alleges that Incyte infringes
several of its patents, and Incyte denies such infringement, and Incyte alleges
that Affymetrix infringes several of its patents, and Affymetrix denies such
infringement;
WHEREAS, the Matters involve claims that numerous complex products and
processes infringe numerous sophisticated patents;
WHEREAS, the Parties acknowledge that the litigation of the Matters
involves substantial uncertainties;
WHEREAS, while the Parties disagree whether infringement exists in the
Matters, each of the Parties acknowledges that there is substantial risk that it
will be found to infringe the other's valid patents;
WHEREAS, the Parties have been involved in various other disputes
involving Stanford University, which have led to the commencement of certain
actions and proceedings, including, but not limited to, Incyte Pharmaceuticals,
Inc., et al. v. Affymetrix, Inc., Case No. C 99-21111 JF (N.D. Cal.); Xxxxxxx 0.
Xxxxx, et al. v. Stephen P.A. Xxxxx, et al., Patent Interference No. 104,358
(Bd. of Patent App. and Inter.); Xxxxxxx 0. Xxxxx, et al. v. Stephen P.A. Xxxxx,
et al., Patent Interference No. 104,359 (Bd. of Patent App. and Inter.), the
Affymetrix Opposition to European Patent No. EP B10804 731, and the Affymetrix
opposition to Australian Patent No. AU709276 (2962/95) (collectively, the
"Stanford Matters");
WHEREAS, the Parties desire to reach an amicable resolution of the
Matters in a voluntary, convenient, efficient and expeditious manner; and
WHEREAS, contemporaneously with the execution of this Agreement, Incyte
and Affymetrix have entered into the following agreements, all of even date
herewith: an *** from *** to *** (the "***"), a *** Agreement under which ***
with respect to certain of *** intellectual property (the "*** Agreement"), a
*** Agreement from *** to *** (the "*** Agreement"), and an *** Agreement under
which *** grants to *** licenses
1
***CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
with respect to certain of *** intellectual property (the "***"). The ***, the
*** Agreement, the *** Agreement, and the *** are collectively referred to
herein as the "Related Agreements".
NOW THEREFORE, for and in consideration of the complexity of the issues
to be litigated and the substantial risks and uncertainties enumerated above,
the Related Agreements, the promises contained herein, and for other good and
valuable consideration, the sufficiency of which is hereby acknowledged, the
Parties agree as follows:
1. Definitions.
-------------
1.1 General Terms. For purposes of this Agreement, the following terms
---------------
have the meanings hereinafter indicated:
"Affymax" means Affymax, Inc., Affymax Research Institute, and/or any
predecessor in interest or successor in interest to either of them.
"Affymetrix Patents" means (a) the Affymetrix Patents-In-Suit, (b) all
patents and/or patent applications claiming priority to or common priority with
the Affymetrix Patents-In-Suit, together with all continuations,
continuations-in-part and divisionals of such patents and patent applications,
and (c) all patents issuing from any patent application described in clause (b),
and (d) all reissues, re-examinations, extensions and foreign counterparts of
any of the foregoing patents and patent applications.
"Affymetrix Patents-In-Suit" means U.S. Patent Nos. 5,445,934,
5744,305, 5,800,992, 5,871,928 and 6,040,193.
"Affiliates" means any company, partnership, corporation or like
entity, in any country, which, directly or indirectly (i) wholly or
substantially owns or controls an entity, directly or indirectly, or (ii) is
wholly or substantially owned or controlled by that entity, directly or
indirectly, but for so long as such entity remains an Affiliate of a Party, and
only if such Affiliate is bound by the terms of this Agreement. As used herein,
substantial ownership or control means ownership or control of one hundred
percent (100%) of the voting stock or equity of an entity and effective
management control by contract or otherwise.
"Claims" means any and all claims, counterclaims, causes of action,
demands, agreements, contracts, covenants, representations, warranties,
promises, undertakings, actions, obligations, controversies, debts, costs,
expenses, attorneys' fees, expert witness fees, court costs, accounts, damages,
losses, injuries and liabilities, of whatever kind or nature, in law, equity, or
otherwise, whether known or unknown, suspected or unsuspected, for or by reason
of any matter, cause or thing whatsoever, whether sounding in contract, tort or
otherwise.
"lncyte Patents" means (a) the Incyte Patents-In-Suit, (b) all patents
and/or patent applications claiming priority to or common priority with the
Incyte Patents-In-Suit, together with all continuations, continuations-in-part
and divisionals of such patents, and/or patent applications; (c) all patents
issuing from any patent application described in clause
2
***CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
(b), and (d) all reissues, re-examinations, extensions and foreign counterparts
of any of the foregoing patents and patent applications.
"Incyte Patents-In-Suit" means U.S. Patent Nos. 5,716,785, 5,891,636,
and 6,291,170.
"Matters" has the meaning specified in the Recitals, above.
"Stanford Matters" has the meaning specified in the Recitals.
2. Release by Incyte.
-------------------
2.1 Except to the extent provided in Sections 8.7 and 9, and except as
provided in Section 11, Incyte, for itself and its present and former officers,
directors, employees, agents, assigns, predecessors, representatives,
subsidiaries, affiliates, and divisions, (collectively, the "Incyte Releasing
Parties"), does hereby forever and irrevocably release, acquit, discharge, and
covenant not to xxx or bring or maintain against Affymetrix, its present and
former officers, directors, employees, predecessors, representatives,
subsidiaries, affiliates and divisions (the "Affymetrix Released Parties") any
Claims based upon events occurring up to and including the Effective Date that
were or could have been asserted in the Matters or that relate to the patents
that are licensed in the Related Agreements. This release specifically covers
any claim voluntarily dismissed in the Matters, but excludes any claims or
contentions relating to the Stanford Matters.
2.2 Except to the extent described in Section 2.5, Incyte, for itself
and the other Incyte Releasing Parties, also hereby forever and irrevocably
releases, acquits, and discharges, and covenants not to xxx or bring or maintain
any Claim against, any customers, collaborators, agents and users of any of the
Affymetrix Released Parties that the Incyte Releasing Parties have, had, or may
have against any of them exclusively arising out of the making, using,
importing, selling, or offering to sell any Affymetrix microarray-related
product manufactured by Affymetrix or the purchase of Affymetrix
microarray-related services prior to and including the Effective Date. For the
sake of clarity, "making, using, importing, selling, or offering to sell any
Affymetrix microarray-related product manufactured by Affymetrix" shall include
any activities performed in conjunction with using an Affymetrix
microarray-related product manufactured by Affymetrix, but such release shall
not extend to any such person's making, using, importing, selling or offering to
sell any microarray-related products other than microarray-related products
manufactured, or sold by Affymetrix.
2.3 Except to the extent described in Section 2.5, Incyte, for itself
and the other Incyte Releasing Parties, also hereby forever and irrevocably
releases, acquits and discharges, and covenants not to xxx or bring or maintain
any Claim against any customers, collaborators, agents or users of any of the
Affymetrix Released Parties based upon the use of microarray-related products
that were sold by Affymetrix on or before the Effective Date and used by such
customer, collaborator, agent or user after the Effective Date. This release
also specifically covers the use of data generated by the use of
microarray-related products that were sold by Affymetrix on or before the
Effective Date and used by such customer, collaborator, agent or user after the
Effective Date.
3
2.4 The release by Incyte set forth in Sections 2.1, 2.2, and 2.3
shall be binding on any successors in interest to Incyte only with respect to
Claims that were or could have been asserted by Incyte (expressly excluding
claims that could only have been asserted by such successor in interest).
2.5 The release by Incyte set forth in Sections 2.2 and 2.3 does not
include any release by Incyte of any Claim that it may have against Invitrogen
Corporation.
3. Release by Affymetrix.
-----------------------
3.1 Except as provided in Section 11, Affymetrix, for itself and its
present and former officers, directors, employees, agents, assigns,
predecessors, representatives, subsidiaries, affiliates, and divisions,
(collectively, the "Affymetrix Releasing Parties"), does hereby forever and
irrevocably release, acquit, discharge, and covenant not to xxx or bring or
maintain against Incyte, its present and former officers, directors, employees,
predecessors, representatives, subsidiaries, affiliates and divisions (the
"Incyte Released Parties") any Claims based upon events occurring up to and
including the Effective Date that were or could have been asserted in the
Matters or that relate to the patents that are licensed in the Related
Agreements. Notwithstanding the foregoing, it is expressly agreed and understood
by the Parties that Incyte Released Parties does not include Xxxxxxx Xxxxx or
Stanford University, and also does not include *** except the release
specifically covers any acts and/or omissions that *** performed within the
course and scope of his employment with Incyte or Synteni. This release
specifically covers any claim or matter dismissed in the Matters, but excludes
any claims or contentions relating to the Stanford Matters. Affymetrix agrees
not to bring any claim against *** for theft of trade secrets,
misappropriation, fraud or any similar causes of action for a period of one (1)
year after the Effective Date unless *** first initiates an action against
Affymetrix. The Parties agree that if Affymetrix asserts such claims, Incyte
will not assert any defenses such as laches, waiver, estoppel or any applicable
statute of limitations based on Affymetrix's delay in filing such claims from
the Effective Date of this Agreement and for the one (1) year period thereafter.
Incyte expressly reserves all other defenses based on Affymetrix' s delay in
filing such claims prior to the Effective Date.
3.2 Except to the extent described in Section 3.5, Affymetrix, for
itself and the other Affymetrix Releasing Parties, also hereby forever and
irrevocably releases, acquits, and discharges, and covenants not to xxx or bring
or maintain any Claim against, any customers, collaborators, agents and users of
any of the Incyte Released Parties that the Affymetrix Releasing Parties have,
had, or may have against any of them exclusively arising out of the making,
using, importing, selling, or offering to sell any Incyte microarray-related
product manufactured by Incyte or the purchase of Incyte microarray-related
services prior to and including the Effective Date. For the sake of clarity,
"making, using, importing, selling, or offering to sell any Incyte
microarray-related product manufactured by Incyte" shall include any activities
performed in conjunction with using an Incyte microarray-related product
manufactured by Incyte, but such release shall not extend to any such person's
making, using, importing, selling or offering to sell any microarray-related
products other than microarray-related products manufactured or sold by Incyte.
4
***CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
3.3 Except to the extent described in Section 3.5, Affymetrix, for
itself and the other Affymetrix Releasing Parties, also hereby forever and
irrevocably releases, acquits, and discharges, and covenants not to xxx or bring
or maintain any Claim against any customers, collaborators, agents or users of
any of the Incyte Released Parties based upon the use of microarray related
products that were purchased from Incyte by such customer, collaborator, agent
or user on or before the Effective Date and used by such customer, collaborator,
agent, or user after the Effective Date. This release also specifically covers
the use of data generated by the use of microarray-related products that were
sold by Incyte on or before the Effective Date and used by such customer,
collaborator, agent or user after the Effective Date.
3.4 The release by Affymetrix set forth in Sections 3.1, 3.2 and 3.3
shall be binding on any successors in interest to Affymetrix only with respect
to Claims that were or could have been asserted by Affymetrix (expressly
excluding claims that could only have been asserted by such successor in
interest).
3.5 The release by Affymetrix set forth in Sections 3.2 and 3.3 does
not include any release by Affymetrix of any Claim that it may have against ***
or *** or any of their respective predecessors in interest or successors in
interest, except with respect to the use by such entities of Incyte' s data for
internal research purposes.
4. Section 1542 Waiver. The Incyte Releasing Parties and the Affymetrix
-------------------
Releasing Parties have each been fully advised by their respective attorneys of
the contents of Section 1542 of the Civil Code of the State of California, which
reads as follows:
"Section 1542. (General Release - Claims Extinguished) A general
release does not extend to claims which the creditor does not know or
suspect to exist in his favor at the time of executing the release,
which if known by him must have materially affected his settlement with
the debtor."
The Incyte Releasing Parties and the Affymetrix Releasing Parties each expressly
waive and relinquish all rights and benefits under Section 1542, and any similar
law or common law principle of similar effect of any state or territory of the
United States and any foreign jurisdiction, with respect to the Claims released
hereby, and expressly consent that this Agreement will be given full force and
effect according to each and all of its express terms and provisions based upon
events occurring up to and including the Effective Date of this Agreement,
including with respect to the release of any Claims that are unknown or
unsuspected that the Incyte Releasing Parties or the Affymetrix Releasing
Parties may have against any of the Released Parties.
5. Finality of Waiver. The Parties hereby expressly and knowingly
------------------
acknowledge that each may, after execution of this Agreement, discover facts
different from or in addition to those which each knows or believes to be true
as of the Effective Date with respect to the Claims released in this Agreement.
Nonetheless, each Party agrees that this Agreement shall be and remain in full
force and effect in all respects, notwithstanding such different or additional
facts. It is the intention hereby fully, finally, and forever to settle and
release all such matters, and any and all Claims relating to the Matters, which
do now exist or previously have existed by and among the Parties. In furtherance
of such intention, the
5
***CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
releases given in this Agreement shall be and remain in effect as full and
completed releases of such matters, notwithstanding the discovery by any of the
Parties of the existence of any additional or different Claims or facts relating
to the Claims occurring prior to and including the Effective Date of this
Agreement. Similarly, in entering into this Agreement, each Party assumes the
risk of mistake, and if either Party should subsequently discover that any fact
it relied upon in entering into this Agreement was untrue, or that its
understanding of the facts or law was incorrect, such Party shall not be
entitled to set aside this Agreement or be entitled to recover any damages on
that account. This Agreement, and the Releases it contains, is intended,
pursuant to the advice of independently selected legal counsel, to be final and
binding between and among the Parties to this Agreement regardless of any claims
of mistake of fact or law or of any other circumstances whatsoever.
6. Dismissals/Withdrawals.
-----------------------
6.1 Except as provided in Section 11, the Parties agree to dismiss
with prejudice all Claims asserted against one another in the Matters.
6.2 The Parties agree that within three (3) business days of the
execution of this Agreement, they will jointly sign and file with the United
States District Court for the Northern District of California the Stipulation
and [Proposed] Order of Dismissal With Prejudice attached hereto as Exhibit A.
6.3 In the event that the Court has not entered the Stipulation and
[Proposed] Order of Dismissal With Prejudice in substantially the form set forth
in Exhibit A within thirty (30) days after its filing, the Parties agree to
contact the Court jointly and use their best efforts in order to expedite entry
of the Stipulation and [Proposed] Order of Dismissal With Prejudice.
6.4 Either Party shall have the right to terminate this Agreement and
the Related Agreements should (i) the Court not enter the Stipulation and
[Proposed] Order of Dismissal With Prejudice in substantially the form set forth
in Exhibit A or (ii) any other government agency or other entity prevents the
Court's entry of such Stipulation and [Proposed] Order of Dismissal With
Prejudice. In the event of termination pursuant to this section:
(a) Any Party who has received a payment from the other Party
pursuant to this Agreement, or the Related Agreements, must return the payment
within seven (7) business days.
(b) Each Party reserves its rights to seek an extension of the
discovery period in the Matters based upon, but not limited to, any arguments
that existed prior to the Effective Date.
6.5 Incyte agrees to take, within fourteen (14) days after the entry
of the Stipulation and [Proposed] Order of Dismissal With Prejudice, all
necessary steps to withdraw from, discontinue, terminate or dismiss the Incyte
Opposition to European Patent No. EP 0619321 and that it will not further
participate directly or indirectly in such opposition.
6.6 The Parties represent and warrant that there are no adverse
proceedings between them that are filed, pending or planned other than the
Matters and the Stanford
6
Matters. If any adverse proceeding was omitted from the Matters and the Stanford
Matters, the parties intend to settle any such litigation, proceeding or action
and therefore agree to take all necessary steps to withdraw from, discontinue,
terminate or dismiss such omitted adverse proceeding.
7. Payment by Affymetrix.
----------------------
7.1 Affymetrix hereby agrees to pay Four Million Five Hundred Thousand
Dollars ($4,500,000) to Incyte as past damages with respect to the Xxxxxx Patent
Rights [as such term is defined in the *** Agreement] within thirty (30) days
after the Effective Date by wire transfer in immediately available federal funds
to an account designated in writing by Incyte.
8. Representations and Indemnities.
--------------------------------
8.1 Each Party to this Agreement represents and warrants to the others
that, as of the date hereof, it is a corporation, duly organized, validly
existing and in good standing under the laws of the jurisdiction of its
incorporation and has all requisite power and authority, corporate or otherwise,
to execute, deliver and perform this Agreement and all Related Agreements. This
Agreement and each of the Related Agreements is a legal, valid and binding
obligation enforceable against each of the Parties in accordance with its terms
and conditions, except as such enforceability may be limited by applicable
bankruptcy, insolvency, moratorium, reorganization or similar laws, from time to
time in effect, affecting creditor's rights generally and by general principles
of equity.
8.2 Each Party to this Agreement represents and warrants that it has
not assigned or transferred any portion of any Claims released under this
Agreement to any other person, individual, firm, corporation or entity. Each
Party to this Agreement further represents and warrants that no other person,
individual, firm, corporation or entity has any lien, right, claim or interest
in any Claims released under this Agreement with the exception of the interests
of Stanford University, Xxxxxxx Xxxxx and Xxxx Xxxxxx in Counterclaim III for a
Declaration That Synteni Or Xxxx Xxxxxx Have Not Misappropriated Any Of
Affymetrix's Trade Secrets. Each Party to this Agreement shall indemnify,
defend, and hold harmless any other Party to or beneficiary of this Agreement
from and against any and all Claims arising out of, related to, or connected
with any prior assignment or transfer, or any purported assignment or transfer,
of any Claims released under this Agreement or breach of the warranties provided
herein.
8.3 Except for statements expressly set forth in this Agreement, no
Party has made any statement or representation to any other Party regarding a
fact relied upon by the other Party in entering into this Agreement and no Party
has relied upon any statement, representation, or promise of any other Party, or
of any representative or attorney for any other Party, in executing this
Agreement or in making the settlement provided for in this Agreement.
8.4 Incyte represents and warrants to Affymetrix and the Affymetrix
Released Parties that, as of the date hereof, it is the successor, owner, and
assignee of Synteni, Inc. and has all requisite power and authority, corporate
or otherwise, to release and discharge all Claims on Synteni's behalf under
Section 2.1, 2.2, and 2.3 to the extent such Claims exist.
7
***CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
Incyte shall indemnify, defend, and hold harmless Affymetrix, each of the
Affymetrix Released Parties, and each beneficiary of this Agreement from and
against any and all Claims arising out of, related to, or connected with any
breach or failure of this representation and warranty.
8.5 Incyte represents and warrants to Affymetrix and the Affymetrix
Released Parties that, as of the date hereof, it possesses the right to assert
the Incyte Patents, and has all requisite power and authority, corporate or
otherwise, to release and discharge any and all Claims relating to infringement
of the Incyte Patents under Sections 2.1, 2.2, and 2.3 to the extent such Claims
exist. Incyte shall indemnify, defend, and hold harmless Affymetrix, each of the
Affymetrix Released Parties, and each beneficiary of this Agreement from and
against any and all Claims arising out of, related to, or connected with any
breach or failure of this representation and warranty.
8.6 Affymetrix represents and warrants to Incyte and the Incyte
Released Parties that, as of the date hereof, that Affymetrix has all the
requisite power and authority, corporate or otherwise, to release and discharge
all Claims on Affymax' behalf under Sections 3.1,3.2 and 3.3 to the extent that
such Claims exist. Affymetrix shall indemnify, defend and hold harmless Incyte,
each of the Incyte Released Parties and each beneficiary of this Agreement from
and against any and all claims arising out of, related to or connected with any
breach or failure of this representation and warranty.
8.7 Incyte represents and warrants to Affymetrix and the Affymetrix
Released Parties that under Incyte's license agreement with Stanford University
("Stanford"), effective March 24, 1995, as amended (the "Stanford Agreement"),
Incyte is obligated to (a) *** with the *** and *** of *** and *** licensed
to Incyte under the Stanford Agreement, including but not limited to ***
involving such *** and *** and appeals thereof; (b) take all steps necessary
to protect the enforceability of such patents; (c) file all documents and
provide all reasonable assistance to Stanford in connection with any of the
foregoing, and (d) ***. Incyte further represents and warrants to Affymetrix
and the Affymetrix Released Parties that Stanford has communicated to Incyte
that *** of the Stanford Matters *** and *** from the Stanford Matters would
constitute *** described in the previous sentence. Incyte shall indemnify,
defend, and hold harmless Affymetrix, each of the Affymetrix Released Parties,
and each beneficiary of this Agreement from and against any and all Claims
arising out of, related to, or connected with any breach or failure of this
representation and warranty:
8.8 Incyte waives any and all rights or interests it may have based on
paragraphs 4.1 and 4.3 of the Loan Agreement between Incyte and *** dated May 7,
1999 (the "*** Agreement"), or any other agreement, which would require or
otherwise provide incentive, either positive or negative, to *** to provoke or
maintain interference proceedings in the U.S. Patent and Trademark Office or any
other adverse proceedings against patent applications or patents assigned to
Affymetrix, and agrees not to (i) enforce any such rights it may have to require
or otherwise provide incentive, either positive or negative, to *** to provoke
or maintain such interference proceedings or (ii) require any monetary
compensation in connection with the settlement or resolution of any interference
proceeding brought by *** against Affymetrix. Incyte agrees to notify *** in
writing of this
8
***CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
provision, and agrees that Affymetrix may show this provision to ***, but not
any other provision of this Agreement or any other agreement between Incyte and
Affymetrix. Incyte shall also execute and deliver to Affymetrix on or before
January 15, 2002 a release letter in the form to be mutually agreed to by the
Parties for the benefit of ***. Incyte expressly reserves all other rights in
the *** Agreement.
8.9 Within ten (10) court days of the Effective Date, Affymetrix will
cause Affymax to file a Request for Dismissal with Prejudice of Affymax'
Complaint For Breach Of Contract; Intentional Interference With Contractual
Relations; And Inducing Breach of Contract, Case No. CV 803311, filed on
November 21,2001, against Xxxxxxx Xxxxxxx, Incyte Genomics, Howrey Xxxxx Xxxxxx
& White, and Does 1 through 10 in the Superior Court of the State of California
for the County of Santa Xxxxx.
9. Stanford Matters.
-----------------
Incyte agrees that it will *** the Stanford Matters to the ***.
10. Cross-Default.
--------------
Except as provided in any provisions of the Related Agreements, the
Parties acknowledge and agree that a breach or default under any of such Related
Agreements shall not constitute a breach or default under any other Related
Agreement nor under this Agreement.
11. Reservation of Rights.
----------------------
Nothing in this Agreement or the Related Agreements shall be
interpreted as an admission by either party of the validity or invalidity of any
patent, or as an admission by either party of its direct or contributory or
inducement of infringement of any patent, or as an admission by either party of
any issue relating to the Matters or Stanford Matters. Notwithstanding any other
provision in this Agreement or the Related Agreements, it is expressly
understood that neither party is waiving or has waived any Claim or affirmative
defense that any patents are valid, invalid, enforceable, or unenforceable,
including any Claim or affirmative defense based upon the factual allegations
made in the Matters or the Stanford Matters which each party expressly reserves.
12. Miscellaneous.
--------------
12.1 The Parties agree to keep the terms of this Agreement and the
Related Agreements confidential, and agree not to disclose the terms of this
Agreement and the Related Agreements, except pursuant to a mutually-agreed press
release, and except as may be (i) necessary for the purpose of enforcing any
provision of this Agreement or a Related Agreement, (ii) required by law or any
regulatory body, and (iii) to the outside counsel of any third party undertaking
a bona fide due diligence exercise in connection with the business of either
Party or the purchase of substantially all of the assets of the other party, but
only where a mutually satisfactory confidentiality agreement has been signed.
Notwithstanding the foregoing, both Parties may agree to inform any court with
jurisdiction over the Matters or Stanford Matters of the existence of a
settlement and the Parties may file this Agreement and any other Related
Agreements in the U.S. Patent office as required
9
***CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
under 35 U.S.C. ss. 135(c). If this Agreement or any of the Related Agreements
is sought in;. discovery, the Party responding to discovery shall make its best
efforts to maintain the confidentiality of the Agreement, and in the event that
a court orders production of the Agreement, to ensure that it is produced with a
restriction providing that it can be seen and/or discussed only by outside
counsel of the requesting party.
12.2 Each Party represents and acknowledges that it has read this
Agreement and fully understands and agrees to its terms, and that each Party has
been represented by counsel in connection with the negotiation and execution of
this Agreement.
12.3 This Agreement may be executed in counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and
the same instrument.
12.4 The Parties agree that this Agreement will be governed by and
construed in accordance with the laws of the State of California applicable to
agreements made and to be performed entirely within such State, without regard
to the conflicts of laws principles of such State.
12.5 This Agreement and the Related Agreements contain the entire
agreement among the Parties with respect to the matters contained herein, and
may be amended only by written agreement signed by the Parties to the Agreement.
The provisions of all of such agreements shall be construed together so as to
give effect to the provisions of each of the agreements to the greatest extent
possible.
12.6 Except to the extent provided in Sections 2.2, 2.3, 3.2, 3.3 and
8.7, this Agreement is intended only for the benefit of the Parties hereto, the
Incyte Released Parties and the Affymetrix Released Parties and no other person
or entity is entitled to any rights or benefits hereunder.
12.7 Each Party shall perform any further acts, and sign and deliver
any further instruments and documents, as may be required to accomplish the
purposes of this Agreement; provided, however, that nothing in this provision
shall be interpreted to modify any of the specific terms of this Agreement.
12.8 Any notice, requests, delivery, approval or consent required or
permitted to be given under this Agreement shall be in writing and shall be
deemed to have been sufficiently given if delivered in person, transmitted by
commercial overnight courier, or transmitted by telex telegram or telecopy
(facsimile, with confirmed receipt) to the Party to whom it is directed at its
address shown below or such other address as such Party shall have last given by
notice to the other Parties (referred to herein as "notice"). All notices shall
be effective upon receipt.
If to Incyte: FAX Number: 000-000-0000
Incyte Genomics, Inc.
0000 Xxxxxx Xxxxx
Xxxx Xxxx, Xxxxxxxxxx 00000
Attention: Xxxx X. Xxxxxxxx, M.D., CEO
with a copy to: Incyte Genomics, Inc.
10
0000 Xxxxxx Xxxxx
Xxxx Xxxx, Xxxxxxxxxx 00000
Attention: Xxx Xxxxxxxxx, General Counsel
If to Affymetrix: FAX Number: 000-000-0000
Affymetrix, Inc.
0000 Xxxxxxx Xxxxxxxxxx
Xxxxx Xxxxx, Xxxxxxxxxx 00000
Attention: Xxxxxxx P.A. Xxxxx, Ph.D.
with a copy to: Affymetrix, Inc.
0000 Xxxxxxx Xxxxxxxxxx
Xxxxx Xxxxx, Xxxxxxxxxx 00000
Attention: Xxxxxxx X. Xxxxxxxxx, Esq.
12.9 No Party hereto shall assign or delegate any of its rights or
obligations hereunder without the prior, written consent of the other Party,
which the other Party may withhold in its sole and absolute discretion, except
that no such consent shall be required with respect to a merger, consolidation,
reorganization, sale of stock or sale of substantially all of the business and
assets of a Party. This Agreement shall be binding upon the permitted successors
and permitted assigns of the Party. Any assignment not in accordance with the
above shall be void.
12.10 The prevailing Party in any action to enforce this Agreement
will be entitled to recover its attorney's fees and costs in connection with
such action.
12.11 Within 90 days after final judgment and appeal or final
settlement of Case No. C 99-21111, the Parties will return and/or destroy all
documents and materials produced in the various actions, and will certify their
destruction and/or return to the other Party, and comply with Section VII of the
Stipulation and Amended Protective Order for Confidential Documents, Testimony
and Information in Cases C 99-21164, C-99- 21165 and C 99-21111 and Amended
Protective Order for Confidential Documents, Testimony and Information in Case C
01-20065. The Parties hereby confirm that, consistent with the terms of the
Protective Orders in the Matters and in Incyte Pharmaceuticals, Inc., et al. v.
Affymetrix, Inc., Case No. C 99-21111 IF (N.D. Cal.), the Parties will not
disclose or use any documents, testimony or other information designated by the
other Party under the Protective Orders except as permitted by the Protective
Orders.
12.12 Incyte and Affymetrix agree that they will not use any
information or materials obtained pursuant to the Protective Orders in the
Matters or Stanford Matters except in those matters, and that they will not
disclose any such information or materials to, or use them on behalf of, any
other person or entity, except as permitted by the Protective Orders referenced
in Section 12.11.
12.13 Except to the extent specifically provided in any of the Related
Agreements, Incyte and Affymetrix agree that for a period of one (1) year from
the Effective Date neither Incyte nor Affymetrix will initiate, sponsor, finance
or participate in any court proceeding or arbitration against the other Party
relating to intellectual property rights.
11
12.14 During the two year period commencing on the first anniversary
of the Effective Date, neither Incyte nor Affymetrix will initiate, sponsor,
finance or participate in any court proceeding or arbitration relating to the
intellectual property rights against the other Party without first engaging in
the following procedures:
(a) The Party which desires to initiate, sponsor, finance or
participate in any such court proceeding or arbitration shall first notify the
other Party in writing of its intention to do so, which notice shall contain a
brief but reasonably complete description of the nature of the claims to be
brought in such court proceeding or arbitration (the "Dispute Notice").
(b) During a period of ninety (90) days from the date of the
Dispute Notice, the Chief Executive Officers of Incyte and Affymetrix shall
discuss the matters described in the Dispute Notice with a view to resolving
such matters in a manner satisfactory to the Parties. If, at the conclusion of
such ninety-day period no resolution has been reached, either Party may
initiate, sponsor, finance or participate in any court proceeding or arbitration
legally available to it.
12.15 In the event of any controversy or claim relating to, arising
out of or in any way connected to any provision of this Agreement ("Dispute"),
except for any proceedings in the United States Patent Office, the Parties shall
seek to settle their differences amicably between themselves. Any unresolved
Dispute shall be resolved by arbitration under 35 U.S.C. 294. The parties agree
that under 35 U.S.C. 294(c), in the event a patent which is the subject of an
arbitration award is subsequently determined to be invalid or unenforceable by a
court or governmental body of competent jurisdiction from which no appeal can or
has been taken such arbitration award may be modified by any court of competent
jurisdiction upon application by a party to the arbitration. Whenever a Party
shall decide to institute arbitration proceedings, it shall give written notice
to that effect to the other Party. The Party giving such notice shall refrain
from instituting the arbitration proceedings for a period of ten (10) days
following such notice to allow the Parties to attempt to resolve the Dispute
between themselves. If the Parties are still unable to resolve the dispute, the
Party giving notice may institute the arbitration proceeding before JAMS or its
successor pursuant to the United States Arbitration Act 9 U.S.C. ss. 1 et seq.
Arbitration shall be held in the San Francisco Bay Area of California. The
arbitration shall be conducted in accordance with the provisions of JAMS
Comprehensive Arbitration Rules and Procedures before a single arbitrator
mutually chosen by the Parties, but if the parties have not agreed upon a single
arbitrator within fifteen (15) days after notice of the institution of the
arbitration, then a single arbitrator shall be chosen under JAMS rules from
neutrals who have experience trying patent cases. All arbitrator(s) eligible to
conduct the arbitration must undertake in writing as a condition of service to
render their opinion(s) promptly after the final arbitration hearing and to
provide a reasoned written opinion setting forth the findings of fact and
conclusions of law. No arbitrator shall have the power to award punitive damages
or any award of multiple damages under this Agreement and such awards are
expressly prohibited. Judgment on the award of the arbitrator(s) may be entered
County of Santa Clara, California. Except to the extent entry of judgment and
any subsequent enforcement may require disclosure, or except as required by law,
all matters relating to the arbitration, including the award, shall be held in
confidence by the Parties.
12
IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
executed in counterparts as of the date first written above.
Dated: AFFYMETRIX, INC.
12/21/01 By: /s/ Xxxxxxx X. Xxxxxxxxx
------------------------------- -------------------------------
Name: XXXXXXX X. XXXXXXXXX
--------------------------
Title: Exec. V.P. & G.G.
--------------------------
Dated: INCYTE GENOMICS, INC.
December 21, 2001 By: /s/ Xxx Bendedgey
------------------------------- -------------------------------
Name: XXX BENDEDGEY
--------------------------
Title: Executive Vice President
--------------------------
Dated:
-------------------------------
Dated:
-------------------------------
13
Exhibit A
Stipulation and [Proposed] Order of Dismissal
14
IRELL & XXXXXXX LLP
Xxxxxx Xxx (SBN 70446)
Xxxxxxx xx Xxxx (SBN 128199)
Xxxxxxx X. Xxxxxxxxx (SBN 139435)
1800 Avenue of the Stars
Xxx Xxxxxxx, Xxxxxxxxxx 00000-0000
Attorneys for Affymetrix, Inc.
HOWREY XXXXX XXXXXX & WHITE, LLP
Xxxxxx X. Xxxxxx (SBN 46046)
Xxxxxx X. Xxxxxx (SBN 132360)
Xxx X. Xxxxxxxxx (SBN 125934)
000 Xxxxxxxxxx Xxxxxx
Xxxxx Xxxx, XX 00000
Attorneys for Incyte Genomics, Inc., Incyte
Pharmaceuticals, Inc., and Synteni, Inc.
OTHER COUNSEL LISTED ON SIGNATURE PAGE
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
SAN XXXX DIVISION
-----------------------------------------------------------------------------------------
AFFYMETRIX, INC., Civil Action No. C 99-21164 (JF)
-----------------------------------------------------------------------------------------
Plaintiff/Counterdefendant, Civil Action No. C 99-21165 (JF)
-----------------------------------------------------------------------------------------
vs. Civil Action No. C 01-20065 (JF)
-----------------------------------------------------------------------------------------
SYNTENI, INC. and INCYTE STIPULATION AND [PROPOSED]
-----------------------------------------------------------------------------------------
PHARMACEUTICALS, INC., ORDER OF DISMISSAL
-----------------------------------------------------------------------------------------
Defendants/Counterclaimant.
-----------------------------------------------------------------------------------------
AND RELATED ACTIONS
-----------------------------------------------------------------------------------------
15
WHEREAS Affymetrix, Inc. ("Affymetrix") and Incyte Genomics, Inc.,
Incyte Pharmaceuticals, Inc., and Synteni, Inc. (collectively, "Incyte") have
entered into a confidential settlement which provides a basis for conclusion of
these actions;
THEREFORE, THE PARTIES HEREBY STIPULATE AND AGREE, through their
counsel of record, that:
1. All claims, defenses, and counterclaims in Case Nos. C 99-21164,
C 99-21165, and C 01-20065 are hereby dismissed with prejudice.
However, it is 11 expressly understood that neither party is admitting
the validity or invalidity of any patent, or its direct, contributory,
or inducement of infringement of any patent, or any issue relating
to the above-captioned actions or Case No. C 99- 21111. It is further
expressly understood that neither party is waiving or has waived any
claim, affirmative defense or contention that any patents are valid,
invalid, enforceable or unenforceable, including any claim,
affirmative defense or contention based upon the factual allegations
made in the above captioned-actions or in Case No. C 99-21111. Each
party expressly reserves such issues, contentions, claims and/or
defenses.
2. The parties do not accept, admit, or waive any issue, matter, or
position raised in or relating to these above-captioned actions.
3. Each party shall bear its own attorneys' fees and costs of suit.
4. Case No. C 99-21111 is not being settled or dismissed at this
time. Neither party shall be required to comply with Paragraph VII
of the Stipulations and Amended Protective Orders for Confidential
Documents, Testimony and Information in Case Nos. C 99-21164, C
99-21165, C 99-21111 and C 01-20065 until final termination or
settlement of Case No. C 99-21111.
16
5. This Court shall retain jurisdiction over the implementation of
the parties' settlement, including retaining jurisdiction to order
any appropriate remedy under law or equity.
Dated: December __, 2001 IRELL & XXXXXXX LLP
By:
-------------------------------
Xxxxxxx xx Xxxx
Attorneys for Affymetrix
Dated: December __, 2001 HOWREY XXXXX XXXXXX & WHITE LLP
By:
-------------------------------
Xxxxxx X. Xxxxxx
Dated: December __, 2001 SHEARMAN & STERLING
By:
-------------------------------
Xxxxx X. Xxxxxxx
Attorneys for Incyte Genomics, Inc.
Incyte Pharmaceuticals, Inc., and
Synteni, Inc.
ORDER
IT IS SO ORDERED.
Dated:
----------------------- ----------------------------------
XXX. XXXXXX XXXXX
UNITED STATES DISTRICT JUDGE
17
